NeuroOne Medical Technologies Corp. reported a quarterly loss of $0.03 per share for its fiscal first quarter that ended December 31, 2025, beating the consensus estimate of a $0.04 loss per share. The company’s product revenue reached $2.9 million, exceeding the analyst consensus of $2.68 million and $2.86 million. The loss per share beat was driven by a combination of disciplined cost management and a favorable product mix, while the revenue beat reflected strong demand for the OneRF Ablation System and continued uptake of the company’s drug delivery platform.
Gross margin for the quarter fell to 54.2% from 58.9% in the same period a year earlier, marking a contraction rather than the improvement reported in the original article. The decline was attributed to a shift in pricing mix and higher operating costs, as well as the absence of the $3 million license revenue that the company earned in Q1 2025 from its expanded distribution agreement with Zimmer Biomet. The company’s cash and cash equivalents decreased from $6.6 million at the end of Q4 2024 to $3.6 million at the end of the quarter, underscoring a rapid burn rate.
"Product revenue was $2.9 million in the first quarter of fiscal 2026 compared to product revenue of $3.3 million in the first quarter of fiscal 2025. On a sequential basis, revenue increased 5.5% from $2.7 million in the fourth quarter of fiscal 2025," said Ronald McClurg, Chief Financial Officer. "The company had no license revenue in the first quarter of fiscal 2026, compared to license revenue of $3 million in the first quarter of fiscal 2025, which was derived from the expanded exclusive distribution agreement with Zimmer." The sequential growth reflects a rebound in core product sales, but the year‑over‑year decline of 12.1% highlights the impact of the lost license revenue and a tougher comparison to the large initial stocking order from Zimmer in the prior year.
Management projected fiscal 2026 product revenue of at least $10.5 million, a minimum 17% increase from fiscal 2025. "The company is projecting fiscal year 2026 sales to be at least $10.5 million, which is a minimum 17% increase from fiscal year 2025," said Dave Rosa, President, CEO and Director. The guidance signals confidence in continued adoption of the OneRF system, which has performed nearly half of all ablations since launch in Q1 2026, and in the drug delivery program expected to enter commercial use and clinical studies in Q3 fiscal 2026.
The company disclosed that it faces substantial doubt about its ability to continue as a going concern and that it is non‑compliant with Nasdaq’s minimum bid price requirement, with a deadline of May 4, 2026 to regain compliance. These financial risks, coupled with the margin contraction and loss of license revenue, are likely to weigh heavily on investor sentiment despite the earnings beat.
The expanded distribution agreement with Zimmer Biomet, which began with a $3 million upfront payment in November 2024, remains a key revenue driver. However, the absence of license revenue in the current quarter underscores the volatility of that partnership and the company’s reliance on a single large customer for a significant portion of its top line.
NeuroOne’s cash burn and the Nasdaq delisting risk highlight the company’s fragile financial position, suggesting that management’s guidance may be optimistic relative to the underlying cash flow realities. Investors will likely scrutinize the company’s ability to sustain operations and meet regulatory compliance in the coming months.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.